

15 JUL 2005



PCT/EP2004 / 001209



INVESTOR IN PEOPLE

101542258  
**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 04 MAR 2004

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 22 December 2003

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977  
(Rule 16)

18 JAN 2003

RECEIVED BY FAX

**The Patent Office**16JAN03 E777382-1 D10059  
P01/7700 0.00-0300934.7

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

## 1. Your reference

CRF-GB-1-307

## 2. Patent application number

(The Patent Office will fill in this part)

0300934 7

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

D. Collen Research Foundation, C/O Dienst Prof. Collen, Campus Gasthuisberg, Herestraat 49, 3000 Leuven

Represented by Prof. Collen, Chairman

Patents ADP number (*if you know it*)

8508327 001

If the applicant is a corporate body, give the country/state of its incorporation

Belgium

## 4. Title of the invention

HAEMOSTASIS

5. Name of your agent (*if you have one*)"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

D. Collen Research Foundation

care of:

Prof. D. Collen

Collingham Gardens 28

London SW5 0HN

UK

8508335 001

Patents ADP number (*if you know it*)6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes / No)

Yes

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d)*

Patents Form 1/77

0057906 16-Jan-03 10:44:00

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description 49

Claim(s)

Abstract 1

Drawing(s)

11  
12

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

2

Request for preliminary examination and search (Patents Form 9/77)

1

Request for substantive examination (Patents Form 10/77)

Any other documents  
(please specify)

1 fax cover sheet

1 fee sheet with request for fax back service

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

16.01.03

12. Name and daytime telephone number of person to contact in the United Kingdom

Prof. D. Collen

Tel. 020 72449405 fax 020 72449406

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## HAEMOSTASIS AND THROMBOPOEISIS

### FIELD OF THE INVENTION

5

This invention relates to the control of the primary haemostasis and the modulation of platelet number and platelet function in a subject. More specifically the invention relates to use of pituitary adenylyl cyclase activating peptide (PACAP), its derivatives, mimetics or inhibitors or a platelet receptor, VPCA1, to modulate the primary haemostasis or  
10 thrombopoiesis.

### BACKGROUND OF THE INVENTION

The present invention relates to a new method for prevention and treatment of either  
15 thrombosis or bleeding based on administration of pituitary adenylyl cyclase activating peptide (PACAP) mimetics or inhibitors respectively.

The initial response to interruption of continuity of a blood vessel is defined as primary haemostasis. Platelets play a major role in the pathophysiology of primary haemostasis. The clinical importance of platelets became first obvious when thrombocytopenic  
20 patients who later on were diagnosed as having immune mediated thrombocytopenia (ITP) had purpura. Platelets participate in haemostasis by sealing vascular injuries and by fostering the process of blood coagulation. Not only the number of the platelets is important (thrombocytopenia for whatever reason) but also their intrinsic function upon activation: platelet shape change, adhesion, aggregation and secretion are prerequisites  
25 for normal haemostasis. Congenital or acquired disorders interfering with one of its function can lead to mild to even severe bleeding problems.

Prevention and treatment of bleeding in patients with thrombocytopenia or thrombocytopathia is therefore based on platelet transfusion or medication interfering with platelet number and/or function.

30

1

Platelets play also a role in the development of arterial thrombosis. Disruption of the endothelial cell lining of the vessels exposes adhesive proteins within the subendothelial matrix, leading to platelet attachment. Thereafter platelet spreading occurs as well as platelet secretion. The secretion of the content of platelet granules can stimulate circulating platelets to acquire new adhesive properties. Finally, stimulated platelets interact with one another during platelet aggregation and a platelet-rich thrombus is formed, which can compromise the patency of blood vessels. Furthermore activated platelets accelerate the rate at which coagulation proteins are activated: phospholipids on the platelet surface facilitate thrombin generation and fibrin strand formation.

Arterial and venous thrombosis and their complications including ischemic stroke, acute myocardial infarction and venous thromboembolism, represent the major cause of morbidity and mortality in the developed countries.

Prevention and treatment of thrombosis are therefore based on administration of antiplatelet drugs, anticoagulants or thrombolytic therapy or combinations of them.

The pituitary Adenyllyl Cyclase Activating Peptide (PACAP 1-38) is a 38-amino acid peptide that was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells (1,2). PACAP is part of the vasoactive intestinal polypeptide (VIP)- glucagon- growth hormone releasing factor-secretin superfamily. Its role in biology is probably crucial, since the sequence of PACAP is highly conserved during the evolution from protostome to mammals. PACAP is widely expressed: in the central and peripheral nervous system, the urogenital system, the gastro-intestinal tract, several endocrine glands. Also PACAP receptors are widely distributed (2). Two classes of PACAP binding sites have been characterized on their relative affinities for PACAP and VIP: type I binding sites with high affinity for PACAP ( $K_d = 0.5 \text{ nM}$ ) and much lower affinity for VIP ( $K_d > 500 \text{ nM}$ ) and type II binding sites, which are widely distributed in various peripheral organs, characterized with similar affinities for PACAP and VIP ( $K_d = 1 \text{ nM}$ ). Molecular cloning of PACAP receptors has demonstrated the existence of three distinct receptor subtypes that are abundantly spread in many tissues: the PACAP-specific PAC1 receptor, coupled to different signal transduction systems, and two PACAP: VIP-indifferent VPAC1 and VPAC2 receptors,

which are primarily coupled to adenylyl cyclase. We found that human platelets do express the VPAC1 receptor. The exact biological and pharmacological function of PACAP has presently been investigated in many organs and tissues as in endocrine glands, central nervous system, respiratory system, cardiovascular system and 5 gastrointestinal tract. Although also extensive studies have been performed on its function in the immune system, no data are available concerning its function on haemostasis.

We have recently found that PACAP has an important function in primary haemostasis: platelet number as well as platelet function are highly influenced by PACAP.

10

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### Brief description of the drawings

**Figure 1. Family presentation.** Squares, male; circles, female; filled symbols, affected 15 individuals; open symbols, unaffected individuals. The proband is indicated with an arrow. Black filled symbols represent members with severe mental retardation and a partial trisomy 18p and monosomy 20p, striped boxes represent members with borderline IQ and the balanced translocation t(18;20) (p21,p13) while question marks stand for members with unexplained mental retardation but unknown karyotype.

20

**Figure 2. Platelet aggregation and adenylyl cyclase activity.** A.  $IC_{50} \pm$  accuracy values for indicated individuals and the mean  $IC_{50}$  value for Iloprost in the platelet aggregation inhibition test with 2  $\mu$ g/ml collagen in 22 controls were calculated. A significantly ( $P < 0.03^*$  or  $P < 0.0076^{**}$ ) lower  $IC_{50}$  value indicates a Gs hyperfunction. The right column of 25 this table illustrates the significantly decreased response to collagen ( $\mu$ g/ml) for respectively IV:5 and V:3 ( $P < 0.003^*$ ) versus V:4 and VI:1 ( $P < 0.0001^{**}$ ) compared to 10 controls or IV:6. EC<sub>50</sub> is expressed as collagen concentration that induces aggregation with amplitude 50 % of maximal aggregation. B. Measurements of cAMP levels under basal conditions performed in duplicate (left panel) or after stimulation with Iloprost (1 30 ng/ml) for various time intervals (right panel) in platelets from VI:1 (■) or an unrelated control (\*). C. Measurements of cAMP levels under basal conditions performed in

duplicate (left panel) or after stimulation with isoproterenol (1  $\mu$ M) for various time intervals (right panel) in fibroblasts from VI:1 (■), a patient with trisomy 18 (▲) or an unrelated control (\*). All cAMP measurements were performed in the presence of the phosphodiesterase inhibitor IBMX (400  $\mu$ M).

5

-----  
Figure 3: Localization of the PACAP gene by FISH. Two-color FISH with probe Y841G3 (green) and two centromeric probes for chromosome 18 and 20 (red) for patient VI:1 and his mother V:3. The arrows point to the PACAP signals.

10 **Figure 4. PACAP detection in fibroblasts and plasma.** A. Semi-quantitative RT-PCR using 20 cycles showed PACAP(1-38) overexpression in fibroblasts from patient VI:1 compared with two controls.  $\beta$ -actin is the internal control. B. PACAP detections by ELISA in plasma from citrate (left panel) or ACD (right panel) blood show pronounced or moderately increased PACAP level in respectively VI:1 (■) and V:4 (▲) or IV:5 (●)  
15 and V:3 (◆) versus a citrated plasma pool (\*) or IV:6 (◊). C. Collagen induced aggregation of control platelets in plasma from a control or from patient IV:1 (two experiments shown).

20 **Figure 5. Role of PACAP(6-38) in platelet aggregation.** A. Dose-dependent stimulatory effect of PACAP(6-38) on collagen-induced (0.2  $\mu$ g/ml) platelet aggregation. B. The platelet aggregation inhibition test with collagen (2  $\mu$ g/ml) and different concentrations of Iloprost (ng/ml) as indicated in the absence (left panels) and presence (right panels) of PACAP(6-38) for a control (upper panels) or patient VI:1 (lower panels).

25 **Figure 6. Effect of anti-PACAP antibodies in mice.** Platelet aggregation was performed in PRP pooled from five mice of each group with  $250 \times 10^3$  plt/ $\mu$ l. A. Stimulatory effect of a polyclonal anti-PACAP antibody (10  $\mu$ g/ml) on collagen-induced (0.35  $\mu$ g/ml) platelet aggregation. B. The platelet aggregation inhibition test with collagen (2  $\mu$ g/ml) and preincubation of Iloprost (10 ng/ml) for mice injected with the indicated antibodies.  
30 C. Platelet aggregation induced with a low concentration of collagen (0.2  $\mu$ g/ml) for mice injected with the indicated antibodies.

**Figure 7.** The mean platelet number per  $\mu\text{l}$  for mice ( $n=5$ ) injected with either polyclonal anti-PACAP (A) or an irrelevant anti- $\beta 2$ -glycoprotein I (B) antibody was determined 14 days after the first antibody injection.

5

**Figure 8.** Mean platelet number +/- SD for mice ( $n=5$ ) injected with either polyclonal anti-PACAP (A) or anti-vWF (75H4B12) (B) antibody determined at the indicated days.

**Figure 9.** Mean platelet number/ $\mu\text{l}$  +/- SD for mice ( $n=5$ ) injected with either polyclonal 10 anti-PACAP (A) or an irrelevant anti-XLas (B) polyclonal antibody determined at the indicated days. Data represent separated experiments A and B.

#### PACAP overexpression in patients

##### 15 Patient descriptions.

We describe a family characterised by an unbalanced segregation of the reciprocal translocation t(18,20) (p21,p13), of which different members suffer from unexplained mental retardation (Figure 1). The propositus (VI:1) is a 23-year-old boy with a hypogonadotropic hypogonadism and is followed for epilepsy, severe mental retardation, 20 hyperactive behavior and hypotonia. He has an increased bleeding tendency and the Ivy bleeding time was markedly prolonged ( $> 15$  minutes) but coagulation studies are normal. Electron microscopy of his platelets is completely normal but he presented on different occasions with a moderate thrombocytopenia, as his platelet count is always about  $70-90 \times 10^3$  platelets/ $\mu\text{l}$ . His karyotype shows a partial trisomy 18p and monosomy 25 20p. His brother (VI:2), father (V:2) and maternal grandmother (IV:6) are phenotypically normal, have no bleeding problems and have a normal karyotype. In contrast, his mother (V:3) and maternal grandfather (IV:5) have no obvious neurologic abnormalities but a borderline IQ. They carry the balanced translocation t(18,20) (p21,p13). They don't have any obvious bleeding problems and have a normal platelet count. His 47-year-old uncle 30 (V:4) also suffers from severe mental retardation, pronounced recurrent epistaxis and cryptorchidism. Furthermore, he frequently has gastric bleedings and his platelet count is

5

around  $150 \times 10^3$  platelets/ $\mu\text{l}$ . He also has a partial trisomy 18p and monosomy 20p. Two other family members (IV:2 and V:1) are known with unexplained mental retardation but from these individuals no DNA samples or further clinical information are available.

5 Adenylyl cyclase activity in platelets and fibroblasts

The propositus VI:1 has disturbed platelet function with a gain-of-Gs activity measured by the platelet aggregation inhibition test, similar to what we described for patients with the XL $\alpha$ s insertion (3,4). Platelets from the patients (VI:1 and V:4) with the partial trisomy 18p/monosomy 20p had a significantly increased sensitivity towards a Gs 10 agonist, the prostacyclin analogue Iloprost (Figure 2A), while platelets from the family members (IV:5 and V:3) with the balanced translocation showed a moderately increased sensitivity. The IC<sub>50</sub> value for member IV:6 with the normal karyotype is within the range of the IC<sub>50</sub> values from 22 unrelated controls.

An important difference between patients from this family and the patients with 15 the XL $\alpha$ s insertion is their decreased sensitivity towards the platelet agonist collagen. The collagen concentration to obtain 50 % aggregation for platelets from V:4 and VI:1 is significantly higher than for platelets from unrelated controls or the normal member IV:6 (Figure 2A). The reactivity of platelets from IV:5 and V:3 towards collagen is again mildly affected.

20 For patients with the XL $\alpha$ s insertion, we demonstrated that the functional responses mediated by stimulation of Gs agonists are due to hyperactivity of adenylyl cyclase only when Gs-coupled receptors are stimulated (3,4). These patients had normal basal cAMP levels. We hypothesized that in the platelets of the propositus VI:1, adenylyl cyclase is already activated under basal conditions. In addition to an increased cAMP 25 response to Iloprost, patient VI:1 indeed shows higher basal cAMP levels (Figure 2B). We also performed cAMP measurements in fibroblasts from VI:1 and found a similar increased basal and stimulated cAMP response (Figure 2C).

PACAP(1-38) mRNA and protein overexpression

30 Patient VI:1 has a normal Gs $\alpha$  mRNA and protein expression level and the coding sequence for the Gs $\alpha$  gene and XL-exon1 were completely normal. Since this patient had

a partial trisomy 18p and monosomy 20p, these chromosomes were screened for candidate genes. Interestingly, measurement of the adenylyl cyclase activity in fibroblasts from an unrelated patient with a complete trisomy 18 showed similarly increased basal and stimulated cAMP levels (Figure 2C). The gene for PACAP (*ADCYAPI*) is located on chromosome 18p31-32 (5) and is a possible candidate since its active peptide, PACAP(1-38), stimulates Gs-coupled receptors and thereby activates adenylyl cyclase. FISH analysis with YAC clone Y841C3 (6), that contains *ACDYAPI*, showed that the translocation results in three copies of the gene in patients VI:1 and V:4 (Figure 3).

10 Human skin fibroblasts express PACAP(1-38) and the PACAP type1-receptor (VPAC1) (7). PACAP(1-38) mRNA was overexpressed in fibroblasts from patient VI:1 (Figure 4A) by semi-quantitative RT-PCR. No PACAP mRNA was found in platelets by RT-PCR, probably due to their unstable RNA. However, we could show by western blot analysis that platelets express the VPAC1 receptor (data not shown). The active peptide  
15 PACAP (1-38) is mainly expressed in testis and brain but this peptide can cross the blood-brain barrier and is stably transported in plasma through coupling with ceruloplasmin (8,9). PACAP(1-38) was detected in human plasma by ELISA and significantly higher levels were found in patients VI:1 and V:4, and moderately increased levels in IV:5 and V:3, in contrast to a plasma pool of unrelated controls or IV:6 (Figure  
20 4B). Platelet aggregation using washed control platelets resuspended in citrated plasma from a control or patient VI:1, indicated that plasma from VI:1 inhibits the collagen induced aggregation (Figure 4C). This could be due to the increased amount of PACAP(1-38) in this plasma.

25 Role for PACAP in platelet aggregation

To determine the effects of the Gs agonist PACAP(1-38) as an inhibitor of collagen induced platelet aggregation, we performed additional aggregations with its antagonist PACAP(6-38). This recombinant peptide has a 10-100 times higher affinity for the VPAC1 receptor than PACAP(1-38) but seems not to activate adenylyl cyclase (2).  
30 PACAP(6-38) activates the collagen-induced platelet aggregation in a dose-dependent manner (Figure 5A). In the presence of PACAP(6-38), basal cAMP levels are 10-20 %

lower (data not shown). The functional platelet aggregation inhibition test for a control person in the presence of PACAP(6-38) results in a Gs loss-of-function (Figure 5B). The influence of PACAP(6-38) on the platelet aggregation test for patient VI:1 was not that pronounced, probably because his PACAP plasma levels were too high.

5

Role for PACAP in platelet aggregation by studies in mice.

Functional platelet studies from patient VI:1 show that increased levels of PACAP(1-38) in plasma result in increased basal cAMP levels and a platelet hypofunction. The role of PACAP(1-38) in platelet function was also studied in mice by 10 subcutaneous injection of polyclonal or monoclonal anti-PACAP antibodies. These antibodies had a similar effect on platelet aggregation as the PACAP antagonist PACAP(6-38). Platelets incubated with anti-PACAP antibodies (10 µg/ml) show an enhanced response towards collagen stimulation (Figure 6A). Moreover, when mice were functionally tested by platelet aggregation 7 days after their last injection, mice treated 15 with anti-PACAP antibodies show the opposite phenotype to that observed in patient VI:1. In contrast to the treatment with the aspecific antibody against β2-glycoprotein I, anti-PACAP-treated mice show a weaker response towards activation of the Gs pathway and have an enhanced response towards collagen stimulation (Figure 6B,C).

20 **Role of PACAP in thrombocytopenia**

As the above described patient was also thrombocytopenic, we hypothesized that PACAP(1-38) or increased cAMP levels could lead to a defective megakaryocyte maturation. The role of PACAP(1-38) in thrombopoiesis was further studied in mice by 25 subcutaneous injection of polyclonal or monoclonal anti-PACAP antibodies. The mice injected with the anti-PACAP antibodies (group A, n=5) have furthermore increased platelet numbers in contrast to the control group (group B, n=5) ( $1194 \pm 237 \times 10^3$  plt/µl versus  $722 \pm 178 \times 10^3$  plt/µl, p= 0.01 - unpaired T-test) (Figure 7).

30 This experiment was repeated but now the platelet number was determined during the experiment at different time points (days 0, 3, 7, 9, and 14) by tail bleeding (figure 8).

Mice injected with anti-PACAP antibodies (at day 0, 3, and 7) and already show increased platelet numbers 3 days after antibody injection.

We studied the increased thrombopoiesis after pre-treatment with a polyclonal anti-  
5 PACAP antibody under conditions of chemically suppressed bone marrow by the agent busulfan. This was done by subcutaneous injection of mice with either a polyclonal anti-  
PACAP or a control polyclonal antibody (at days 0, 3, and 7) and afterwards an intraperitoneal injection of Busulfan (20 mg/kg) (at days 8 and 11). The platelet number  
was counted at different time points and we found that mice pretreated with the  
10 polyclonal anti-PACAP antibody recovered more rapidly from their thrombocytopenic condition than the mice injected with the control antibody (Figure 9A,B).

#### References to this application

- 15 1. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. *Biochem Biophys Res Commun* 1989; 164: 567-574.
2. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. *Pharm Rev* 2000; 52: 269-324.
- 20 3. K Freson, MF. Hoylaerts, J Jaeken, M Bysen, J Amont, J Vermylen, C Van Geet. Genetic variation of the extra-large stimulatory G protein  $\alpha$ -subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding. *Thrombosis and Haemostasis* 86:733-738 (2001)
- 25 4. Freson K, Jaeken J, Van Helvoort M, de Zegher F, Wittevrongel C, Thys C, Hoylaerts MF, Vermylen J, Van Geet C. Functional polymorphisms in the paternally expressed XL $\alpha$ s and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Submitted
- 30 5. Hosoya M, Kimura C, Ogi K, Ohkubo S, Miyamoto Y, Kugoh H, Shimizu M, Onda H, Oshimura M, Arimura A, Fujino M. Structure of the human pituitary adenylate

- cyclase-activating polypeptide (PACAP) gene. *Biochim Biophys Acta* 1992; 1129: 199-206.
6. Chang E, Welch S, Luna J, Giacalone J, Francke U. Generation of a human chromosome 18-specific YAC clone collection and mapping of 55 unique YACs by FISH and fingerprinting. *Genomics* 1993; 17: 393-402.
- 5 7. Steinhoff M, McGregor GP, Radleff-Schlittmeier A, Steinhoff A, Jarry H, Schmidt WE. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. *Regul Pept* 1999; 80: 49-55
- 10 8. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. *J Pharmacol Exp Ther* 1993; 267: 690-696.
9. Tams JW, Johnsen AH, Fahrenkrug J. Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin. *Biochem J* 1999; 341: 271-276.
- 15

## HAEMOSTASIS AND THROMBOPOEISIS

### ABSTRACT

5

The present invention relates to a new method for prevention and treatment of either thrombosis or bleeding based on administration of pituitary adenylyl cyclase activating peptide (PACAP) mimetics or inhibitors respectively or by activating or blocking  
10 respectively of a platelet receptor, VPCA1.

11

0057906 16 Jan 03 10:47

Fig 1.





Fig. 2


A

	$IC_{50} \pm SD$ Iloprost	$EC_{50} \pm SD$ Collagen
IV:6	$0.96 \pm 0.002$	$0.25 \pm 0.012$
IV:5	$0.50 \pm 0.003^*$	$0.74 \pm 0.013$
V:3	$0.47 \pm 0.003^*$	$0.75 \pm 0.008$
V:4	$0.27 \pm 0.005^*$	$1.08 \pm 0.006$
VI:1	$0.34 \pm 0.004^{**}$	$1.03 \pm 0.008$
Controls	$1.04 \pm 0.39$ ( $n = 22$ )	$0.22 \pm 0.6$ ( $n = 10$ )

B



C



**Fig. 3.**






Fig 4



**Fig. 5.**




Fig. 6





Fig. 7



7/9

Fig. 8







Fig. 9



PCT/EP2004/001209



---

---

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**